Pharmaceutical Technology on MSN
Outlook Therapeutics receives FDA response on ONS-5010 for wet AMD
The ONS-5010 BLA resubmission was supported by data from the NORSE programme, including NORSE TWO and other trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback